News

Adagene Showcases Promising Results for ADG126 in Cancer Trials

Adagene Showcases Promising Results for ADG126 in Cancer Trials

Exploring the Latest ADG126 Combinations in Colorectal Cancer

Adagene Inc. (Nasdaq: ADAG), renowned for innovating in the field of antibody-based therapies, has revealed encouraging new data regarding its investigational treatment ADG126, also known as muzastotug. Presenting at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting, the company outlined findings from its Phase 1b/2 study, which highlights the effectiveness of ADG126 when combined with pembrolizumab, also known as KEYTRUDA.

Safety and Efficacy of ADG126

One of the standout pieces of information from the study indicates that ADG126 can be safely administered at a dose of 20 mg/kg every six weeks with an impressive safety profile. Reports noted that less than 20% of patients experienced Grade 3 adverse events, which is a significant achievement in cancer therapy, where toxicity can often limit treatment options.

Overall Response Rate Indicates Promising Outcomes

Significantly, the combination treatment showed a confirmed overall response rate (ORR) of 29% in patients who were diagnosed with microsatellite stable colorectal cancer (MSS CRC). Out of the six patients who responded positively in the 20 mg/kg cohorts, all remain under treatment, with four of those patients continuing for over 40 weeks.

Survival Metrics

Furthermore, patients receiving the 10 mg/kg dosage displayed a median overall survival (OS) of 19.4 months after a follow-up period of 17.8 months. Not only does this figure speak volumes regarding the durability of the response, but it also provides a hopeful outlook for patients impacted by advanced stages of this difficult-to-treat cancer.

Expert Insights and Future Directions

Dr. Marwan Fakih, a noted Professor of Medical Oncology and Therapeutics Research, commented on the findings, emphasizing the reduced treatment-related toxicities associated with the higher dosage. He remarked on the sustained efficacy observed in patients exhibiting responses, suggesting a noteworthy potential for long-term treatment benefits.

Adagene's CEO, Peter Luo, Ph.D., also expressed optimism regarding these results, highlighting the importance of predictive pharmacokinetics and pharmacodynamics in shaping treatment regimens tailored to individual patient needs. This innovative approach offers patients continued access to therapies with minimized side effects, paving the way for enhanced quality of life during their treatment journey.

Patient Cohort Insights

As of the last update, 67 MSS CRC patients, including a subset with peritoneal involvement, have participated in the trial. The doses administered include 10 mg/kg or the tested 20 mg/kg in combination with KEYTRUDA, known for its anti-PD-1 properties. This strategic combination aims to maximize therapeutic effects while carefully observing patient safety as a priority.

Next Steps in Clinical Development

With the continued maturation of data on the 20 mg/kg cohorts, Adagene is eagerly anticipating discussions with regulatory bodies to finalize dosing regimens for forthcoming phases of clinical development. These pivotal conversations will seek to validate the dosing strategies demonstrated to be effective and safe, propelling ADG126 closer to potential market approval.

ASCO Presentation Overview

The exciting data were presented in a poster titled "Safety and Efficacy of ADG126 in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRC," during a scheduled viewing at the ASCO Annual Meeting. This event promises to continue highlighting innovative research within the oncology community.

About Adagene and Its Vision

Adagene is a pioneering biotechnology company that integrates advanced computational biology and artificial intelligence to develop novel antibody-drafted cancer therapies aimed at addressing unmet medical needs. Their SAFEbody technology illustrates how personalizing therapies can minimize toxicity while delivering effective treatments.

ADG126, as a non-toxic anti-CTLA-4 SAFEbody specifically targeting regulatory T cells in tumors, encapsulates Adagene’s dedication to providing next-generation immunotherapies for patients battling colorectal cancer among other indications.

Frequently Asked Questions

What is ADG126 and its relevance in cancer treatment?

ADG126 is a novel antibody-based therapy designed to target CTLA-4, enhancing the immune response against cancer cells, particularly in colorectal cancer.

What were the key results presented at ASCO regarding ADG126?

The study presented showed a 29% overall response rate in colorectal cancer patients with a favorable safety profile, indicating potential for significant therapeutic benefit.

What safety measures are associated with ADG126?

ADG126 has demonstrated low incidences of Grade 3 adverse events, showing a promising safety profile compared to traditional cancer therapies.

What is the future direction of the ADG126 clinical trials?

Adagene plans to engage with regulatory authorities to discuss the dosing regimen based on the promising data collected, moving towards further clinical development.

How can patients find more information about Adagene?

Patients and interested parties can visit Adagene's dedicated investor section on their website for up-to-date information on their ongoing clinical trials and innovative therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Magnetron Solutions for Peak RF Performance

Updated Category News Views 129

Revolutionizing RF Power with Advanced Magnetron Transmitters In the realm of radio frequency (RF) technology, Diversified Technologies, Inc. (DTI) has unveiled a groundbreaking solid-state magnetron transmitter, which utilizes a novel Marx modulator. This innovative approach allows users to finely tune the pulse wave, enhancing overall performance and adaptability for...

Continue Reading
Lineage Inc. Strengthens Financial Agreements and Growth Potential

Updated Category News Views 142

Lineage Inc. Updates Financial Agreements for Greater Flexibility Lineage, Inc., a real estate investment trust recognized for its expertise in logistics, has made important changes to its financial agreements to bolster its financial standing. By adding more subsidiaries as obligors, the company demonstrates its flexibility and growth strategy. Recently, Lineage grabbed...

Continue Reading
Super League Achieves Major Financial Milestones in 2025

Updated Category News Views 394

Super League Reports Impressive Financial Growth Super League has recently showcased remarkable financial improvements, marking a significant turnaround in its operations. This comes on the heels of the company achieving a robust balance sheet powered by strategic investments, including a $20 million private placement and, notably, having zero debt. These developments not...

Continue Reading
Michael Lachmann's 'Spacetime Capsule' Documentary Now Streaming

Updated Category News Views 241

Michael Lachmann's Innovative Documentary Series The new documentary series, Spacetime Capsule, directed by British filmmaker Michael Lachmann, has recently premiered on popular Chinese video platforms. This captivating series, produced by China Review Studio, consists of three episodes that creatively employ the concept of a "spacetime capsule" to frame its narrative,...

Continue Reading
Innovative Leaders of Tomorrow: The 2025 TIME100 Next List

Updated Category News Views 395

TIME Introduces the Inspiring 2025 TIME100 Next List Tate McRae to Perform at the Upcoming TIME100 Next Event In a recent announcement, TIME has unveiled its exciting 2025 TIME100 Next list, spotlighting a diverse group of 100 emerging leaders from across the globe. These individuals are not only shaping the future but are also redefining leadership norms within their...

Continue Reading